Fig. 6
From: Efficacy of galcanezumab in migraine central sensitization
CSI score changes categorized by the responder rate. The mean CSI scores were significantly decreased (from baseline) at 3 and 6 months in the non-responders (responder rate < 30%) and good responders (responder rate ≥ 50%). CSI: Central Sensitization Inventory; NS: not significant.
